Arvinas has announced encouraging phase 1 data for its investigational PROTAC degrader ARV-102, showing that the treatment achieved more than 50% degradation of LRRK2 in the cerebrospinal fluid of people with Parkinson’s disease after 28 days. The findings were presented at the AD/PD 2026 conference in Copenhagen.
The company said the trial demonstrated that ARV-102 reduced endolysosomal and neuroinflammatory biomarkers associated with Parkinson’s and progressive supranuclear palsy, while also being well tolerated across all dose levels. The multiple dose cohort assessed daily oral doses ranging from 20 mg to 80 mg.
Andrew Siderowf, Chair of the Parkinson Study Group, said: “These data represent exciting progress in the Parkinson’s disease treatment landscape. Importantly, ARV-102’s reduction of LRRK2 protein levels and other key biomarkers in patients with Parkinson’s disease suggests that PROTACs may offer a path for future treatment approaches. I look forward to following the continued advancement of ARV-102 and what it could bring for patients.”
According to Arvinas, ARV-102 exposure in cerebrospinal fluid increased in a dose-dependent manner, confirming brain penetration. The compound achieved the targeted level of LRRK2 reduction by day 14 at all doses, with effects maintained through day 28. No serious adverse events were reported, and all treatment-emergent events were mild.
Noah Berkowitz, Chief Medical Officer of Arvinas, said: “We are pleased to see compelling and consistent data that reinforce the continued development of ARV-102 as a potential treatment for neurodegenerative diseases like Parkinson’s disease and progressive supranuclear palsy that profoundly impact millions of patients and their families worldwide.
“To our knowledge, this level of biomarker modulation has not previously been demonstrated by LRRK2 inhibitors, and we believe these data serve as the first of its kind.”
Arvinas plans to begin a phase 1b study in progressive supranuclear palsy in the second quarter of 2026, with the potential to move into a registrational trial later in the year.
